Drug Trial Radar · NCT06312176
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,200
Planned (sponsor's estimate)
Start
Apr 14, 2024
Primary completion
Jul 11, 2027
Study completion Apr 12, 2031
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Mar 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth factor receptor-2 negative (HR+/HER2-) unresectable locally advanced, or metastatic, breast cancer. The primary hypotheses are that sacituzumab tirumotecan as a single agent and sacituzumab tirumotecan plus pembrolizumab are superior to TPC with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR) in all participants.
Conditions
- Breast Neoplasms
Interventions
Sacituzumab tirumotecanDrug
IV infusion
PembrolizumabBiological
IV infusion
PaclitaxelDrug
IV infusion
Nab-paclitaxelDrug
IV infusion
CapecitabineDrug
oral tablet
Liposomal doxorubicinDrug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) ( sacituzumab tirumotecan versus treatment of physician's choice [TPC]; pembrolizumab + sacituzumab tirumotecan versus TPC)Time frame: Up to ~40 months
- PFS (Sacituzumab tirumotecan + pembrolizumab versus TPC)Time frame: Up to ~40 months
Locations
259 sites in 40 countries. Site status is shown where the registry gives one.
Ironwood Cancer & Research Centers ( Site 0066)
Chandler, Arizona · Recruiting
Banner MD Anderson Cancer Center-Oncology ( Site 0004)
Gilbert, Arizona · Recruiting
Providence Medical Foundation-Oncology ( Site 0020)
Fullerton, California · Recruiting
Moores Cancer Center ( Site 0059)
La Jolla, California · Active not recruiting
Cancer and Blood Specialty Clinic ( Site 0001)
Los Alamitos, California · Active not recruiting
University of Colorado Anschutz Medical Campus ( Site 0061)
Aurora, Colorado · Recruiting
UCHealth Cherry Creek Medical Center ( Site 0094)
Denver, Colorado · Recruiting
University of Colorado Health - Highlands Ranch Hospital ( Site 0095)
Highlands Ranch, Colorado · Completed
Yale Cancer Center ( Site 0060)
New Haven, Connecticut · Active not recruiting
Stamford Hospital ( Site 0049)
Stamford, Connecticut · Recruiting
AdventHealth Altamonte Springs ( Site 0021)
Altamonte Springs, Florida · Recruiting
University of Florida College of Medicine ( Site 0063)
Gainesville, Florida · Active not recruiting
Orlando Health Cancer Institute ( Site 0011)
Orlando, Florida · Recruiting
Archbold Memorial Hospital-Lewis Hall Singletary Oncology Center ( Site 0032)
Thomasville, Georgia · Completed
Rush University Medical Center ( Site 0079)
Chicago, Illinois · Recruiting
University of Chicago Medical Center ( Site 0067)
Chicago, Illinois · Active not recruiting
Saint Elizabeth Medical Center Edgewood-Cancer Care Center ( Site 0053)
Edgewood, Kentucky · Recruiting
Mary Bird Perkins Cancer Center-Breast & GYN Pavilion ( Site 0042)
Baton Rouge, Louisiana · Recruiting
Greenebaum Comprehensive Cancer Center ( Site 0036)
Baltimore, Maryland · Recruiting
Mercy Medical Center - Baltimore-Medical Oncology and Hematology ( Site 0028)
Baltimore, Maryland · Completed
Holy Cross Hospital ( Site 0073)
Silver Spring, Maryland · Recruiting
Dana-Farber Cancer Institute-Breast Oncology Center ( Site 0037)
Boston, Massachusetts · Recruiting
Henry Ford Health ( Site 0002)
Detroit, Michigan · Recruiting
Saint Luke's Cancer Institute ( Site 0027)
Kansas City, Missouri · Recruiting
Washington University School of Medicine ( Site 0076)
St Louis, Missouri · Recruiting
NYU Langone Health - Brooklyn ( Site 0089)
Brooklyn, New York · Recruiting
NYU Langone Hospital - Long Island ( Site 0090)
Mineola, New York · Recruiting
Laura and Isaac Perlmutter Cancer Center-Hematology and Oncology ( Site 0068)
New York, New York · Recruiting
Hematology Oncology Associates of Rockland ( Site 0054)
Nyack, New York · Recruiting
Stony Brook University-Cancer Center ( Site 0034)
Stony Brook, New York · Recruiting
Levine Cancer Institute ( Site 0014)
Charlotte, North Carolina · Recruiting
Zangmeister Cancer Center ( Site 7000)
Columbus, Ohio · Completed
Providence Portland Medical Center ( Site 0044)
Portland, Oregon · Recruiting
Providence St. Vincent Medical Center ( Site 0081)
Portland, Oregon · Recruiting
Thomas Jefferson University - Clinical Research Institute ( Site 0056)
Philadelphia, Pennsylvania · Recruiting
Texas Oncology-Dallas Presbyterian Hospital ( Site 8000)
Dallas, Texas · Recruiting
Parkland Health and Hospital System ( Site 0069)
Dallas, Texas · Recruiting
UT Southwestern Medical Center ( Site 0050)
Dallas, Texas · Recruiting
The Center for Cancer and Blood Disorders ( Site 0041)
Fort Worth, Texas · Recruiting
Texas Oncology - San Antonio ( Site 8002)
San Antonio, Texas · Recruiting
Showing 40 of 259 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.